X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the expanded collaboration, Kite has exercised its option to negotiate a license for Arcellx's ARC-SparX program, ACLX-001, in multiple myeloma, which is comprised of ARC-T cells and SparX proteins that target BCMA.
Lead Product(s): ACLX-001
Therapeutic Area: Oncology Product Name: ACLX-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Kite Pharma
Deal Size: $285.0 million Upfront Cash: $85.0 million
Deal Type: Expanded Collaboration November 15, 2023
Details:
CART-ddBCMA is Arcellx's BCMA-specific CAR-modified T-cell therapy utilizing the company's novel BCMA-targeting binding domain for the treatment of patients with relapsed or refractory multiple myeloma.
Lead Product(s): CART-ddBCMA
Therapeutic Area: Oncology Product Name: CART-ddBCMA
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 14, 2023
Details:
CART-ddBCMA is Arcellx's BCMA-specific CAR-modified T-cell therapy utilizing the company's novel BCMA-targeting binding domain for the treatment of patients with relapsed or refractory multiple myeloma.
Lead Product(s): CART-ddBCMA
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2023
Details:
Kite and Arcellx were jointly working to advance and commercialize the CART-ddBCMA asset for relapsed or refractory multiple myeloma in U.S., and Kite was supposed to commercialize outside the U.S.
Lead Product(s): CART-ddBCMA
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Kite Pharma
Deal Size: $325.0 million Upfront Cash: $225.0 million
Deal Type: Termination January 30, 2023
Details:
CART-ddBCMA is an investigational cell therapy product comprising autologous T cells that have been genetically modified to target multiple myeloma. CART-ddBCMA utilizes Arcellx’s novel D-Domain binder.
Lead Product(s): CART-ddBCMA
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Kite Pharma
Deal Size: $4225.0 million Upfront Cash: $225.0 million
Deal Type: Collaboration December 09, 2022
Details:
ACLX-001, ARC-SparX is a novel CAR-T cell therapy treatment designed to allow for controllability and adaptability to potentially reduce toxicities associated with serious dose-limiting adverse events and overcome tumor heterogeneity.
Lead Product(s): ACLX-001
Therapeutic Area: Oncology Product Name: ACLX-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2022
Details:
The proceeds will support the company’s development of CART-ddBCMA, a BCMA-specific CAR-modified T-cell therapy currently in Phase 1 and anticipated to begin a pivotal trial in 2022.
Lead Product(s): CART-ddBCMA
Therapeutic Area: Oncology Product Name: CART-ddBCMA
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Samsara BioCapital
Deal Size: $115.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing April 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
